颌骨造釉细胞瘤64例临床分析

本文对我院１９５４－１９９０年收治的６４例颌骨造釉细胞瘤进行了回顾性分析，未发现１例恶性。特别是我们在长期工作实践中发现肿瘤与周围正常骨质有较明显的分界。遂于１９６３年开始试行颌骨内种瘤出术，至１９９０年６月已经成功地施了１２例，１例因手术时肿物巨大而且合并感染于术后１０年复发外，其余１１例术后随访年６个月－２７年，中位１２年１０个月均无复发。发种手术损伤小，方法简单，无损美容，预后性，特别是对颌     

急性脑梗塞患者血清肿瘤坏死因子水平变化的观察

采用双抗体夹心ＥＬＩＳＡ法对３０例正常对照和３６例急性脑梗塞患者血清肿瘤坏死因子（ＴＮＦ）水平进行了检测。结果显示：急性脑梗塞组血清ＴＮＦ水平显著高于正常对照组，血清ＴＮＦ水平变化与脑梗塞容积大小密切相关，恢复期血清ＴＮＦ水平显著降低。结果提示，ＴＮＦ参与了脑梗塞发生后病理变化过程，检测血清ＴＮＦ对判定脑梗塞容积大小有一定的临床意义。     

Effective segmental chemoembolization of advanced hepatocellular carcinoma with tumor thrombus in the portal vein

Purpose: Evaluate therapeutic results of transcatheter segmental hepatic artery chemo-oily-embolization (segmental TAE) against advanced hepatocellular carcinomas (HCC) accompanied by portal tumor thrombus (PTT). Methods: Segmental TAE was performed in nine patients with hepatic cirrhosis and advanced HCCs accompanied by PTT. Four subsegmental portal branches were obstructed by PTT in three patients, and two were obstructed in the remaining six patients. TAE was performed into the targeted segmental hepatic artery followed by embolization with gelatin sponge particles. Results: In one patient undergoing subsequent resection, a marked anticancer effect on the PTT was demonstrated histologically. In the eight other patients who did not undergo subsequent resection, the cumulative survival rates were 67% at 6 months, 44% at 1 year, and 22% at 2 years. No serious complications were noted. Conclusions: This therapeutic approach is thought to be a useful treatment for HCC with PTT, because it reinforces anticancer effects and can be performed more safely than conventional transcatheter arterial embolization.     

Removal of famotidine by haemodialysis in elderly anuric patients

Summary The effect of haemodialysis on the pharmacokinetics of oral famotidine has been studied in five elderly anuric patients. Famotidine 20 mg was administered in a cross-over design to patients on and not on haemodialysis.The elimination rate constant of haemodialysis (k) was 4.6-fold larger than the systemic elimination rate constant (k_e). Although the mean maximum serum concentration of famotidine during haemodialysis (141.5 ng·ml^–1) was not significantly lower than that without haemodialysis (195.6 ng·ml^–1), the AUC up to 5 h during haemodialysis was significantly decreased to 58.1% of the value without it.The data suggest that famotidine is dialysable by haemodialysis.     

大肠黏膜癌变过程中PTEN和p27的表达及相关性研究

目的 :探讨PTEN及p2 7在大肠黏膜癌变过程中的表达及两者的相关性。方法 :采用免疫组织化学S -P法检测了 5 8例大肠癌 ,15例腺瘤性息肉及 11例配对的癌旁正常组织中抑癌基因PTEN和 p2 7的蛋白表达。分析PTEN和 p2 7的表达情况及与各种临床病理特征的关系及两者的相关性。结果 :在癌旁正常组织、大肠腺瘤性息肉、大肠癌组织中PTEN表达率分别为 (97.3± 4 .3) % ,(85 .2± 16 .8) % ,(13.8± 17.6 ) % ,呈递减趋势。大肠癌DukesA/B期组PTEN蛋白的高表达率为 88.9% ,明显高于DukesC/D期组中的 5 1.6 %。PTEN的高表达率与性别、年龄、肿瘤的大小、部位、分化程度、有无淋巴结转移无关。p2 7主要表达在细胞核 ,也有少量表达在细胞浆。在癌旁正常组织、大肠腺瘤性息肉、大肠癌组织中p2 7高表达率分别为 (98.8± 1.0 8) % ,(86 .0± 13.6 ) % ,(5 6 .8± 2 6 .0 ) % ,呈递减趋势。在大肠癌高、中分化组中 p2 7蛋白的表达率为 71.4 % ,明显高于低分化组中的 2 3.1%。p2 7的高表达率与患者的Dukes分期、性别、年龄、肿瘤的大小、部位及有无淋巴结转移无关。在大肠癌组织中 ,PTEN与 p2 7蛋白的表达呈正相关 (r =0 .6 4 2 )。结论 :PTEN及p2 7表达在癌旁正常组织、大肠腺瘤性息肉、大肠癌组织中均呈递减趋势 ,提示P     

肾癌伴下腔静脉癌栓的诊断及治疗（附11例报告）

报告１１例肾细胞癌伴下腔静脉癌栓患者，男９例，女２例；右侧８例，左侧３例。临床症状：血尿９例，腹部肿物２例，仅１例出现下肢水肿、腹壁浅静脉扩张。全部病人均经ＣＴ扫描或ＣＴ和ＭＲＩ检查明确诊断。１０例经上腹正中或胸腹联合切口取出癌栓连同患肾一并切除。５例术前无其它部位转移者术后平均存活５年２个月，１例术后２个月死亡，２例术前肾蒂淋巴结及肾周脂肪侵犯者中１例存活２年５个月死于非肿瘤疾病，１例目前已存活３年１个月尚在，２例失访。本组腔静脉癌栓发生率占同期肾癌病人的２．７％。本组ＣＴ与ＭＲＩ相结合应用诊断符合率为９８０％。     

Preconditions for and consequences of self-determination: the psychiatric patient's point of view

In the context of an interview study concerned with self-determination in psychiatric patients, this paper describes the preconditions for and consequences of self-determination from the point of view of psychiatric patients themselves. The data were collected in semi-structured interviews with long-term psychiatric patients ( n =72) and analysed using the method of content analysis. Responses on the preconditions for self-determination were grouped into three categories: firstly, there were those who said that reference to self-determination in the case of psychiatric patients is nonsense; secondly, there were those who said that self-determination requires no preconditions; and thirdly, there were those who said that there are certain preconditions, such as the ability to think and make decisions, activity, obedience, and illness. Both positive and negative consequences were identified in situations where self-determination is maintained, but only negative consequences in situations where self-determination is lost. On the basis of these tentative results, self-determination seemed to be relevant in psychiatric nursing. We are continuing to develop and test an instrument for the evaluation of the opportunity for self-determination in clinical practice.     

心包内处理肺血管及心房部分切除治疗中心型肺癌

１９８７年５月至１９９３年１２月对１６例较晚期肺癌采用心包内处理肺血管及心房部分切除的方法作了全肺切除术，肿瘤均为中心型。ＣＴ扫描显示隆突下或主肺动脉窗淋巴结肿大者占５０％，术中见肺动脉，肺静脉均受累者８例，肺静脉受累者６例，２例作左心室部分切除，１５例恢复良好，１例术中大出血致心脏停搏，复苏后并发脑水肿昏迷死亡。我们认为，心包内处理肺血管全肺切除提高了手术切除率，且手术过程较安全可靠，作者对这种     

老年重症急性胰腺炎手术治疗探讨

目的：讨论老年重症急性胰腺炎的手术治疗。方法：我院1984年1月－2000年10月共收治60岁以上手术证实的重症急性胰腺炎26例，本对其手术治疗的方法和时机以及相应的并发症和死亡率进行回顾性分析。结果：本组术后死亡6例，其中4例死于MOF，2例死于ARDS。在发病24小时内手术8例中无1例死亡，24－36小时内手术14例有2例死亡，36小时后手术4例均死亡。结论：老年重症胰腺炎患多伴有心、肺、肾等重要器官慢性疾病，脏器代偿功能差，较易出现MOF，因此如有手术指证或经短期非手术治疗效果不明显，应及时手术，并在术中和术后采用合理的治疗措施，有利于减少术后并发症，降低手术死亡率。     

Efficacy of piribedil as early combination to levodopa in patients with stable Parkinson's disease: a 6-month, randomized, placebo-controlled study.

Piribedil is a non-ergot D2/D3 agonist with a significant antagonist action on alpha2A and alpha2C adrenergic receptor subtypes. This double-blind placebo-controlled study was undertaken to confirm the efficacy of 150 mg/day piribedil po in improving motor symptoms of idiopathic Parkinson's disease (PD) in nonfluctuating patients insufficiently controlled by a stable daily dose of levodopa (L-dopa). Efficacy was assessed using the Unified Parkinson's Disease Rating Scale (UPDRS) III score as primary criterion over 4 months. A second comparison was planned at 6 months, after possible adjustment of L-dopa. At 4 months, the rate of response, defined as a 30% decrease from baseline on UPDRS III score, was significantly greater with piribedil compared with placebo (56.4% vs. 37.7%; P = 0.040). At 6 months, the better efficacy of piribedil was maintained (61.8% of responders vs. 39.6% on placebo; P = 0.020). The difference between groups on UPDRS III change from baseline reached statistical significance only at 6 months: -10.0 points in the piribedil group vs. -6.7 points in the placebo group (P = 0.037). Secondary end-points were not significantly different. The most frequently reported adverse events were gastrointestinal symptoms (27 of 61 patients in the piribedil group vs. 13 of 54 patients in the placebo group). In conclusion, a 6-month oral administration of 150 mg/day piribedil in combination with L-dopa is well tolerated, except for minor gastrointestinal symptoms at the beginning of the treatment and significantly improves motor symptoms compared with placebo in PD nonfluctuating patients.